Zanidatamab provides ORR in HER2+ biliary tract cancer Presented ByProf. Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, USA TrialPhase 1 ConferenceASCO GI 2021 TypePeer-reviewed article 12 March 2021 11:28